Exposed VWF binding surface in the spacer domain comprising residues Arg568, Phe592 Arg661, Tyr660, Tyr661, and Tyr665. These residues are targeted by autoantibodies that develop in patients with acquired TTP. Conservative changes in these 5 residues result in a gain-of-function ADAMTS13 variant.